Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07362888 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Adcendo ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07362888: Recruiting Phase 1 study, sponsored by Adcendo ApS.
NCT07362888 is a Phase 1 study that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 180 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07362888, a Phase 1 study, is actively recruiting participants, sponsored by Adcendo ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs)
Interventions
- DRUG ADCE-B05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2029-03-14 |
| Phase | Phase 1 |
What NCT07362888 shows while recruiting
NCT07362888 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 1 intervention - of which ADCE-B05 is the first listed.
NCT07362888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07362888 about?
NCT07362888 is a clinical study titled "First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors". The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
What is the current status of trial NCT07362888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03-17. Estimated completion is 2029-03-14.
What interventions are being tested in trial NCT07362888?
The interventions under investigation include: ADCE-B05 (DRUG).
Who is sponsoring clinical trial NCT07362888?
This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07362888's enrollment target sits among peer trials
180 299th of 2000 higher than 1,690 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI